Translating basic cell and molecular biology towards new medicines

Add to your list(s) Download to your calendar using vCal

• Professor Steve Jackson
• Thursday 19 January 2017, 17:00-18:00
• Department of Biochemistry, Sanger Building Lecture Theatre.

If you have a question about this talk, please contact Yi Lei Tan.

Professor Jackson’s pioneering academic research has enabled the identification of many key principles by which cells respond to and repair DNA damage. Recognising that many DNA damage response proteins represent attractive drug targets, in 1997 Steve founded the drug-discovery company KuDOS Pharmaceuticals Ltd., then served as part-time Chief Scientific Officer (CSO) until and after its acquisition by AstraZeneca in 2006. In 2010, Steve founded Mission Therapeutics Ltd. (Babraham, Cambridge) to exploit recent advances in protein ubiquitylation and deubiquitylation to derive new medicines, particularly for cancer and neurodegenerative diseases, and serves as its part-time CSO . Professor Jackson will be sharing his experience and advice about translating academic research towards patient benefit.

This talk is part of the Seminars at the Department of Biochemistry series.

This talk is included in these lists:

• Cambridge Infectious Diseases
• Department of Biochemistry, Sanger Building Lecture Theatre
• PMRFPS's
• Seminars at the Department of Biochemistry
• biochem seminars
• ndk22's list
• rc781
• se393's list

Note that ex-directory lists are not shown.